Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
10,891 total articles
Assembly Biosciences announced that its Chief Medical Officer, Dr. Anuj Gaggar, will present at the Bank of America Securities 2026 Global Health Care Conference. The presentation will highlight the company's work on innovative small-molecule therapeutics targeting serious viral diseases such as hepatitis B and herpesvirus. The company also provide…
Team, Inc., a leading provider of specialty industrial services, has announced that it will release its first quarter 2026 earnings on May 13, 2026, after NYSE trading hours, followed by a conference call on May 14, 2026 to discuss the financial and operational results.
Trio Petroleum Corp has raised approximately $24 million through its ATM equity program, strengthening its balance sheet to pursue growth via strategic acquisitions, especially in the Canadian oil and gas sector. The company assembled a multidisciplinary team to identify and execute acquisition opportunities, aiming to expand production, reserves, …
FTI Consulting has appointed Emanuele Grasso as Senior Managing Director and leader of its Corporate Finance segment in Italy. Grasso returns to Milan after nearly a decade in New York, bringing over 30 years of experience advising major financial services clients on corporate transactions, M&A, and SPAC deals. His appointment supports FTI's strate…
Apyx Medical Corporation announced that it received expanded FDA 510(k) clearance for its AYON Body Contouring System to include power liposuction, an advanced liposuction technique that enhances fat removal efficiency and reduces surgeon effort and operating room time. The company plans a limited commercial launch to refine utilization prior to br…
Clearmind Medicine Inc., a Nasdaq-listed clinical-stage biotech company, announced a live webinar on June 10, 2026, to present new insights from its FDA-approved Phase I/IIa multi-center clinical trial of CMND-100, a non-hallucinogenic MEAI-based oral drug candidate targeting Alcohol Use Disorder. The webinar will feature leading investigators from…
eXp World Holdings announced its Q1 2026 financial results, reporting $1 billion in revenue, a 5% increase year-over-year, and an 88% rise in Adjusted EBITDA to $4.1 million. The company reduced its net loss per share compared to last year and enhanced operational efficiency. A major strategic milestone was the acquisition of NextHome, expanding it…
Inspira Technologies, trading as IINN on NASDAQ, announced a comprehensive strategic plan focusing on three growth areas: the commercial scaling of its Additively Manufactured Electronics (AME) platform, development of a quantum connectivity program addressing key hardware bottlenecks in quantum computing, and the repositioning and potential moneti…
Bicara Therapeutics released strong Q1 2026 results highlighting progress in their pivotal Phase 2/3 FORTIFI-HN01 trial of ficerafusp alfa for HPV-negative head and neck squamous cell carcinoma. The company plans to initiate a new randomized study of a novel dosing regimen combining ficerafusp alfa and pembrolizumab in Q3 2026, aiming for accelerat…
Dyne Therapeutics reported positive clinical and regulatory progress for its lead drug candidates z-rostudirsen for Duchenne muscular dystrophy (DMD) and z-basivarsen for myotonic dystrophy type 1 (DM1), including positive FDA pre-BLA meeting for z-rostudirsen and initiation of a confirmatory Phase 3 trial. The company is on track for potential dru…
3D Systems announced that ROE Dental Laboratory is significantly expanding its fleet of NextDent 300 3D printers across multiple U.S. sites. This move triples ROE's capacity for manufacturing high-precision, multi-material digital dentures, highlighting rapid adoption of 3D Systems' Jetted Denture Solution and reinforcing its leadership in digital …
ASP Isotopes' subsidiary, Quantum Leap Energy, has entered a non-binding Memorandum of Understanding with a European nuclear technology firm to assess collaboration for supplying high assay low enriched uranium (HALEU), critical for next-generation nuclear reactors. The partnership aims to enable uranium feedstock supply and enrichment services tar…
Beneficient issued a statement following the conviction of its former Chairman and CEO, Brad Heppner, for multiple fraud-related charges connected to a scheme involving GWG Holdings. The Company highlights its swift action upon discovering Heppner's misconduct, full cooperation with authorities, and commitment to moving forward with integrity and s…
Cronos Group Inc. announced its Q1 2026 financial results, reporting a 40% year-over-year increase in net revenue to $45.2 million and achieving record net revenue and gross profit. The company strengthened its market leadership in Canada and Israel, with the Spinach® brand topping vape market share in Canada and PEACE NATURALS® remaining the numbe…
Intellia Therapeutics announced strong Phase 3 topline results for lonvo-z in hereditary angioedema (HAE), showing an 87% reduction in attacks versus placebo. The company initiated a rolling biologics license application (BLA) for lonvo-z with the FDA, targeting a U.S. launch in first half of 2027. Patient screening resumed for Phase 3 trials of ne…
OptimizeRx launched a new programmatic connection linking its proprietary electronic health record (EHR) network to demand-side platforms (DSPs). This enables media buyers in the life sciences sector to activate scalable, point-of-care advertising campaigns directly and efficiently within existing programmatic workflows, expanding access to key cli…
Alterity Therapeutics announced the publication of a peer-reviewed study in NeuroImage demonstrating that quantitative susceptibility mapping (QSM) MRI detects disease-specific iron accumulation in Multiple System Atrophy (MSA), differentiates it from Parkinson's disease, and correlates with clinical severity. The findings support QSM as an objecti…
Encore Capital Group, Inc. announced a proposed private offering of $550 million aggregate principal amount of senior secured notes due 2032. The proceeds from the offering, combined with draws on its revolving credit facility, are intended to redeem existing senior secured notes due in 2028 and 2029, and to cover associated fees. The offering is s…
Invivyd, Inc. announced publication of a new manuscript analyzing early systemic side effects of their investigational monoclonal antibody adintrevimab from the EVADE study, showing minimal tolerability issues compared to higher reactogenicity observed with COVID-19 mRNA and protein vaccines. The research supports epidemiologic comparisons of sympt…
IREN Limited intends to raise $2 billion through a private offering of convertible senior notes due 2033, with an option to issue an additional $300 million. The notes will accrue interest, be convertible under certain conditions, and redeemable subject to conditions. Proceeds will fund capped call transactions to mitigate dilution and general corp…
Apogee Therapeutics announced strong 52-week Phase 2 data for its lead drug candidate zumilokibart in treating atopic dermatitis, demonstrating durable and improved efficacy with extended dosing intervals. The company plans to initiate Phase 3 trials later in 2026 and expand clinical development into asthma and eosinophilic esophagitis indications.…
RoboStrategy, Inc., a closed-end investment fund focusing on robotics and physical AI companies, has begun trading on the NASDAQ under the ticker BOT. The fund offers public investors exposure to a concentrated portfolio of private, pre-IPO, and public robotics firms, bridging the gap between venture capital opportunities and public markets. This d…
Gray Media, Inc. announced the promotion of James Finch to Senior Vice President of News Services in recognition of his 30 years of contributions and increasing responsibilities managing news operations for the company's local TV stations and digital platforms. The company is the largest owner of local television stations in the US, encompassing 12…
Sagimet Biosciences announced preclinical data demonstrating the potential of fatty acid synthase (FASN) inhibitors to reduce sebum production, a key factor in acne. This supports their upcoming Phase 3 clinical trial of denifanstat for moderate to severe acne in the U.S., planned to initiate in the second half of 2026. The data will be presented a…
Actuate Therapeutics announced FDA clearance for an IND to begin Phase 1/2 clinical trials of their oral elraglusib formulation in advanced cancers including metastatic melanoma, NSCLC, colorectal, and pancreatic cancers, aiming to improve patient convenience and drug exposure. The company also revealed plans to study elraglusib in combination with…
